Watch and Read: Dr. Tenenbaum on The Impact of Personalized Medicine

On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The ScientistThe Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:

The Impact of Personalized Medicine from thescientistllc on Vimeo:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.

Panelists:

Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons

Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program

Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center

Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”

 


Dr. Tenenbaum to Speak as Panel Host for The Scientist Magazine's Webinar Series

On Tuesday, May 7, Dr. Tenenbaum will host a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. The series, which began on April 18, takes “a bold look at what the future holds for DNA research, bringing together senior investigators and key leaders in the field of genetics and genomics.” Dr. Tenenbaum will speak during the final webinar, The Impact of Personalized Medicine.

From The Scientist‘s description:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.”

Dr. Tenenbaum will be joined by Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program; and Abhijit “Ron” Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson.

When: Tuesday, May 7, 2013, 2:30–4:00 pm ET. Register here.


Smart Patients Launches Online Community for Cancer Patients and Caregivers

Cancer Commons’ partner Smart Patients launched publicly today after a presentation at the TEDMED conference in Washington, DC. Smart Patients is an online discussion platform for cancer patients and their caregivers that will enable them to learn from each other and improve their care. The free website lets users share insights about personal treatment experiences, discuss breaking science, and search for clinical trials, as shown in this demo video:

 

 

Cancer Commons will be partnering with Smart Patients to bring patients’ insights to our Rapid Learning Communities. Cancer Commons’ research collaborators will be able to access anonymous insights from Smart Patients discussions. These insights will help Cancer Commons in its mission to make sure every cancer patient is treated according to what’s working best for similar patients.

Read more at our Need to Know blog or visit www.smartpatients.com.


Cancer Commons and the $10 Million Prostate Cancer Dream Team

A multicenter “dream team” of scientists, led by the University of California, San Francisco (UCSF), has embarked on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer. The grant is provided by Stand Up To Cancer and the Prostate Cancer Foundation.

Continue reading…


Cancer Commons Featured in The Scientist Magazine

Do-It-Yourself-Medicine: Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?

From the article by Jeff Akst:

“When you have gigabytes of data, perhaps hundreds of gigabytes, for each patient, that’s more data than has existed in all clinical trials combined up until a couple of years ago,” says Marty Tenenbaum, who in 2010 founded Cancer Commons, a database that collates real-time patient data and up-to-the-moment basic medical research to inform cancer treatment.

See the full article here.


CHI and Cancer Commons will present a plenary panel on Personalized Oncology at the Molecular Medicine Tri-Confernce in San Francisco

Plenary Keynotes

Wednesday, February 13
8:00 – 9:40 am

Personalized Oncology – Fulfilling the Promise for Today’s Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future. Continue reading…


Science Exchange/Cancer Commons in BioWorld article

Patients Take the Lead in Clinical Whole Genome Sequencing

From the article by Catherine Shaffer:

“Elizabeth Iorns, a representative of Science Exchange, said many of its providers are CLIA certified, and that the group is planning to expand into clinical services in partnership with Cancer Commons, a nonprofit open science initiative working toward bringing next-generation genomics technologies to patients.”

Read the full article here.


Cancer Commons Featured in SF Business Times

Trial and error: Biotechs, patients, FDA search for faster, cheaper ways to develop drugs.

From the article by Ron Leuty:

“Take Marty Tenenbaum, a metastatic melanoma survivor who has led efforts to link patients, researchers and companies in an open-science initiative, called Cancer Commons. His thinking is the more that patients know clinical trial results — and, importantly, report their own — the faster patients will populate the right clinical trials that are right for them.”

Read more here.


Dr. Tenenbaum to speak at Personalized Medicine World Conference

Dr. Tenenbaum to speak at the Personalized Medicine World Conference on January 28, 2013.
The 5th Annual Personalized Medicine World Conference on January 28-29 in Silicon Valley, provides an opportunity to learn from and engage in dialogue to further the field of personalized medicine. PMWC 2013 will bring together CEOs, entrepreneurs, researchers, clinicians, regulators and payers to present the latest progress and next challenges for the implementation of personalized medicine within a framework to address the coverage barriers. Featuring the premier leaders in the field, the Conference offers an opportunity to share best practices and build on lessons learned.